ASH HIGHLIGHTS 2023 - MULTIPLE MYELOMA ROUNDTABLE DISCUSSION - OncologyEducation

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION

Chair

Dr. Donna Reece

Panelist

Dr. Maria-Victoria Mateos
Dr. Elena Zamagni

Videos

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: PERSEUS Trial

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Iskia Trial

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Optimum / Muknine Trial

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Multiple Myeloma

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: CC-95266, a GPRC5D-Targeted CAR T-Cell Therapy for RRMM

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: The Phase 2 CARTITUDE-2 Trial

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: RRMM Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Prophylactic Tocilizumab to Prevent CRS with Teclistamab Administration

2023

ASH HIGHLIGHTS 2023 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: Results from the Phase 1b MonumenTAL-2 Study

Tagged login-not-required stand-alone